- Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
- Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
More ▼
Key statistics
On Thursday, Exelixis Inc (EXEL:NSQ) closed at 20.41, 9.50% above its 52-week low of 18.64, set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.03 |
---|---|
High | 21.05 |
Low | 20.23 |
Bid | 20.38 |
Offer | 21.36 |
Previous close | 21.00 |
Average volume | 1.81m |
---|---|
Shares outstanding | 291.29m |
Free float | 284.98m |
P/E (TTM) | 32.48 |
Market cap | 6.12bn USD |
EPS (TTM) | 0.6466 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼